Acute Pain News and Research

RSS

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.

2 Jul 2015

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API).

22 Jun 2015

New evidence-based protocol to treat severe pain in emergency department patients

Simply asking the question, "Do you want more pain medication?" resulted in satisfactory pain control in 99 percent of emergency department patients participating in a study.

15 Jun 2015

US patients undergoing orthopaedic surgery receive more treatments for pain

New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally.

1 Jun 2015

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain.

27 May 2015

Specific brain chemical may play role in promoting chronic pain

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas.

7 May 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Markovian models show promise for describing postoperative pain trajectories

Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.

25 Mar 2015

AAPM announces 2015 Presidential Commendations for exceptional service in Pain Medicine

The American Academy of Pain Medicine is pleased to announce its 2015 Presidential Commendations for exceptional service to the Academy and/or the field of Pain Medicine.

23 Mar 2015

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain.

22 Mar 2015

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain.

18 Mar 2015

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04.

16 Mar 2015

New poll finds pain as key correlates of shorter sleep durations, worse sleep quality

A new poll by the National Sleep Foundation finds that pain is a key factor in the gap between the amount of sleep Americans say they need and the amount they're getting - an average 42 minute sleep debt for those with chronic pain and 14 minutes for those who've suffered from acute pain in the past week.

3 Mar 2015

ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals, Inc. today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain.

30 Jan 2015

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.

2 Dec 2014

National Spine & Pain Centers opens new pain management center in Cumberland, Maryland

Over 100 million adults suffer from chronic pain and about half of those suffer from this pain daily. Chronic and acute pain dramatically impacts quality of life. The specialty of pain management is born to fulfill the need for non-surgical, interventional solutions and medication management to treat all types of pain.

26 Nov 2014

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse.

21 Nov 2014

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society.

28 Oct 2014

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment.

29 Sep 2014